TP53突变识别接受CHOP为基础化疗的外周T细胞淋巴瘤高危事件
该回顾性研究纳入132例接受CHOP为基础化疗的结节性外周T细胞淋巴瘤患者,采用MSK-IMPACT二代测序 panel 检测肿瘤突变。多因素分析显示晚期疾病和骨髓受累与进展风险增加相关;仅TP53突变和TP53/17p缺失与无进展生存期(PFS)较差相关,TP53突变组中位PFS为4.5个月 vs 无TP53突变组10.5个月;未发现TP53异常与总生存期(OS)较差相关;CDKN2A缺失(n=9)与OS较差相关,中位17.6个月 vs 无CDKN2A缺失患者56.7个月。
要点
- TP53突变组中位PFS 4.5个月 vs 无TP53突变组10.5个月。
- TP53/17p缺失与PFS较差相关,但TP53异常未显示与OS较差相关。
- CDKN2A缺失(n=9)与OS较差相关,中位17.6个月 vs 56.7个月。
核心结论
- 该回顾性研究提示,携带TP53突变的PTCL患者接受根治性化疗后PFS较差,需前瞻性研究证实。
研究设计与样本
- 回顾性评估接受CHOP为基础化疗的PTCL病例,肿瘤经MSK-IMPACT二代测序panel测序,共纳入132例符合条件患者。
主要发现
- 多因素分析显示,与进展风险增加相关的临床因素包括晚期疾病和骨髓受累。
- 与PFS较差相关的唯一体细胞遗传学异常为TP53突变和TP53/17p缺失。
- 按TP53突变状态分层,TP53突变组(n=21)中位PFS为4.5个月 vs 无TP53突变组(n=111)10.5个月。
- 未发现TP53异常与OS较差相关。
- CDKN2A缺失的PTCL(n=9)与OS较差相关,中位17.6个月 vs 无CDKN2A缺失患者56.7个月。
关键数值与推荐
- TP53突变组(n=21)中位PFS 4.5个月 vs 无TP53突变组(n=111)10.5个月。
- CDKN2A缺失组(n=9)中位OS 17.6个月 vs 无CDKN2A缺失组56.7个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 原文结论指出需前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival. We identified 132 patients who met these criteria. Clinical factors correlating with an increased risk of progression (by multivariate analysis) included advanced-stage disease and bone marrow involvement. The only somatic genetic aberrancies correlating with inferior progression-free survival (PFS) were TP53 mutations and TP53/17p deletions. PFS remained inferior when stratifying by TP53 mutation status, with a median PFS of 4.5 months for PTCL with a TP53 mutation (n = 21) vs 10.5 months for PTCL without a TP53 mutation (n = 111). No TP53 aberrancy correlated with inferior overall survival (OS). Although rare (n = 9), CDKN2A-deleted PTCL correlated with inferior OS, with a median of 17.6 months vs 56.7 months for patients without CDKN2A deletions. This retrospective study suggests that patients with PTCL with TP53 mutations experience inferior PFS when treated with curative-intent chemotherapy, warranting prospective confirmation.
引用
- Johnson WT, Ganesan N, Epstein-Peterson ZD, et al. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood Adv. 2023. PMID: 37078708. doi:10.1182/bloodadvances.2023009953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。